biotricity inc - BTCY

BTCY

Close Chg Chg %
0.29 0.03 9.02%

Open Market

0.32

+0.03 (9.02%)

Volume: 167.61K

Last Updated:

Dec 31, 2025, 2:21 PM EDT

Company Overview: biotricity inc - BTCY

BTCY Key Data

Open

$0.29

Day Range

0.29 - 0.32

52 Week Range

0.23 - 0.83

Market Cap

$8.11M

Shares Outstanding

27.96M

Public Float

17.14M

Beta

1.34

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$0.19

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

104.18K

 

BTCY Performance

1 Week
 
5.07%
 
1 Month
 
-39.80%
 
3 Months
 
-43.90%
 
1 Year
 
-0.31%
 
5 Years
 
-93.48%
 

BTCY Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About biotricity inc - BTCY

Biotricity, Inc. is a medical technology company, which engages in biometric data monitoring solutions. Its products include Bioflux, Biocore, Bioheart, Biokit, and Biocare. The company was founded by Waqaas Al-Siddiq and Peter McGoldrick on January 25, 2011 and is headquartered in Redwood City, CA.

BTCY At a Glance

Biotricity, Inc.
203 Redwood Shores Parkway
Redwood City, California 94065
Phone 1-800-590-4155 Revenue 13.79M
Industry Packaged Software Net Income -8,421,179.00
Sector Technology Services 2025 Sales Growth 14.316%
Fiscal Year-end 03 / 2026 Employees 46
View SEC Filings

BTCY Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 0.531
Price to Book Ratio N/A
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -17.233
Enterprise Value to Sales 2.541
Total Debt to Enterprise Value 0.745

BTCY Efficiency

Revenue/Employee 299,789.00
Income Per Employee -183,069.109
Receivables Turnover 8.314
Total Asset Turnover 2.381

BTCY Liquidity

Current Ratio 0.225
Quick Ratio 0.149
Cash Ratio 0.018

BTCY Profitability

Gross Margin 76.608
Operating Margin -17.759
Pretax Margin -61.066
Net Margin -61.066
Return on Assets -145.399
Return on Equity N/A
Return on Total Capital 214.613
Return on Invested Capital N/A

BTCY Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital -664.907
Total Debt to Total Assets 462.514
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital -345.071
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Biotricity Inc - BTCY

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
7.65M 9.64M 12.06M 13.79M
Sales Growth
+126.02% +26.00% +25.15% +14.32%
Cost of Goods Sold (COGS) incl D&A
3.08M 4.20M 3.71M 3.23M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
68.34K 346.26K 371.85K 415.49K
Depreciation
68.34K 346.26K 371.85K 415.49K
Amortization of Intangibles
- - - -
-
COGS Growth
+64.61% +36.26% -11.67% -12.98%
Gross Income
4.57M 5.44M 8.36M 10.56M
Gross Income Growth
+201.93% +19.08% +53.55% +26.43%
Gross Profit Margin
+59.74% +56.46% +69.27% +76.61%
2022 2023 2024 2025 5-year trend
SG&A Expense
22.04M 20.85M 17.18M 13.01M
Research & Development
2.74M 3.23M 2.57M 2.16M
Other SG&A
19.30M 17.62M 14.61M 10.86M
SGA Growth
+49.82% -5.41% -17.59% -24.27%
Other Operating Expense
- - - -
-
Unusual Expense
1.84M 554.99K (28.32K) 691.79K
EBIT after Unusual Expense
(19.31M) (15.96M) (8.80M) (3.14M)
Non Operating Income/Expense
15.12K (110.82K) (102.61K) (78.57K)
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
9.83M 2.58M 5.19M 5.20M
Interest Expense Growth
+273.46% -73.73% +101.03% +0.20%
Gross Interest Expense
9.83M 2.58M 5.19M 5.20M
Interest Capitalized
- - - -
-
Pretax Income
(29.13M) (18.66M) (14.09M) (8.42M)
Pretax Income Growth
-88.05% +35.95% +24.46% +40.25%
Pretax Margin
-380.78% -193.57% -116.84% -61.07%
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(29.13M) (18.66M) (14.09M) (8.42M)
Minority Interest Expense
- - - -
-
Net Income
(29.13M) (18.66M) (14.09M) (8.42M)
Net Income Growth
-88.05% +35.95% +24.46% +40.25%
Net Margin Growth
-380.78% -193.57% -116.84% -61.07%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(29.13M) (18.66M) (14.09M) (8.42M)
Preferred Dividends
1.09M 875.54K 834.68K 3.52M
Net Income Available to Common
(30.22M) (19.53M) (14.93M) (11.94M)
EPS (Basic)
-3.9894 -2.2557 -1.6603 -0.5548
EPS (Basic) Growth
-51.64% +43.46% +26.40% +66.58%
Basic Shares Outstanding
7.57M 8.66M 8.99M 21.52M
EPS (Diluted)
-3.9894 -2.2557 -1.6603 -0.5548
EPS (Diluted) Growth
-51.64% +43.46% +26.40% +66.58%
Diluted Shares Outstanding
7.57M 8.66M 8.99M 21.52M
EBITDA
(17.41M) (15.06M) (8.46M) (2.03M)
EBITDA Growth
-35.42% +13.45% +43.86% +75.95%
EBITDA Margin
-227.51% -156.28% -70.10% -14.75%

Snapshot

Average Recommendation HOLD Average Target Price 4.00
Number of Ratings 1 Current Quarters Estimate N/A
FY Report Date N/A Current Year's Estimate N/A
Last Quarter’s Earnings -0.03 Median PE on CY Estimate N/A
Year Ago Earnings -0.045 Next Fiscal Year Estimate N/A
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates N/A N/A N/A N/A
Mean Estimate N/A N/A N/A N/A
High Estimates N/A N/A N/A N/A
Low Estimate N/A N/A N/A N/A
Coefficient of Variance N/A N/A N/A N/A

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 0 0 0
OVERWEIGHT 0 0 0
HOLD 1 1 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Hold Hold Hold

Biotricity Inc in the News